Amgen's $13.4bn Otezla Buy Helps Bristol/Celgene Merger Close By Year-End
Amgen sees opportunity to grow Otezla sales through new indications and additional ex-US launches. The deal depends on Bristol closing its Celgene acquisition, pending FTC clearance.
You may also be interested in...
Amgen and Bristol defended their positions in the post-topical/pre-biologic segment of the psoriasis market during their Q4 earnings calls, now that each company has an oral drug available.
Regeneron antitrust suit alleges Amgen’s bundling of Repatha rebates with Otezla and Enbrel has restricted Praluent’s market access and ability to compete with Repatha.
Amgen is enthusiastic about deals of all sizes, including a new Arrakis collaboration, and is interested in large transactions like its Otezla buy – but Bradway said right-priced opportunities are fewer and farther between.